MedTrace Logo

Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment

NCT02082756 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2018-11-14

No results posted yet for this study

Summary

The aim of this study is to assess the beneficial effects of Bifidobacterium and Berberine Hydrochloride on lowering glucose and delaying progress to diabetes in patients with prediabetes and to detect the potential mechanism.

Conditions

Interventions

DRUG

Bifidobacterium viable pharmaceutics

DRUG

Berberine Hydrochloride

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Qiu Ji, Ph.D..M.D. · Department of Endocrinology, Xijing Hospital, Fourth Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02082756 on ClinicalTrials.gov